Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Successful treatment of hairy cell leukemia variant with obinutuzumab
Published in: Annals of Hematology
Access to document
10.1007/s00277-021-04559-z
document
Diana Al-Sarayfi, Freek O. Meeuwes, Thijs Oude Munnink, Wouter Plattel, Stefano Rosati, Estella Matutes, Marcel Nijland
Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome
Published in: Cancers
Access to document
10.3390/cancers14041010
document
Patients with primary Sjogren’s syndrome (pSS) are at risk of developing extranodal marginal zone lymphoma (ENMZL) of the mucosa-associated lymphoid tissue (MALT) in the parotid glands. Unlike recurrent genomic aberrations observed in MALT lymphoma, which were not associated with pSS (non-pSS), it is unknown which somatic aberrations underlie the development of pSS-associated MALT lymphomas. Whole-exome sequencing was performed on 17 pSS-associated MALT lymphomas. In total, 222 nonsynonymous somatic variants affecting 182 genes were identified across the 17 cases. The median number of variants was seven (range 2-78), including...
Johanna A A Bult, Jessica R Plaça, Erlin A Haacke, M Martijn Terpstra, Gwenny M Verstappen, Frederik K L Spijkervet, Frans G M Kroese, Wouter J Plattel, Joost S P Vermaat, Hendrika Bootsma, Bert van der Vegt, Arjan Diepstra, Anke van den Berg, Klaas Kok, Marcel Nijland
Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [F-18]FDG PET/CT features
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-021-05626-3
document
Background One of the challenges in the management of patients with follicular lymphoma (FL) is the identification of individuals with histological transformation, most commonly into diffuse large B-cell lymphoma (DLBCL). [F-18]FDG-PET/CT is used for staging of patients with lymphoma, but visual interpretation cannot reliably discern FL from DLBCL. This study evaluated whether radiomic features extracted from clinical baseline [F-18]FDG PET/CT and analyzed by machine learning algorithms may help discriminate FL from DLBCL. Materials and methods Patients were selected based on confirmed histopathological diagnosis of primary FL (n=44) or...
F Montes de Jesus, Y Yin, E Mantzorou-Kyriaki, X U Kahle, R J de Haas, D Yakar, A W J M Glaudemans, W Noordzij, T C Kwee, M Nijland
Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome
Published in: Blood
Access to document
10.1182/blood-2021-153130
Johanna A. A. Bult, Jessica R. Placa, Erlin A. Haacke, Gwenny M. Verstappen, Frederik K. L. Spijkervet, Frans G. M. Kroese, Wouter J. Plattel, Joost S. P. Vermaat, Hendrika Bootsma, Bert Van der Vegt, Arjan Diepstra, Anke Van Den Berg, Klaas Kok, Marcel Nijland
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2021005215
document
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma subtype. This retrospective study elucidates the currently unknown genetic background of a large clinically well-annotated cohort of DLBCLwith osseous localizations (O-DLBCL), including PB-DLBCL. A total of 103 patients with O-DLBCL were included and compared with 63 (extra)nodal non-osseous (NO)-DLBCLs with germinal center B-cell phenotype (NO-DLBCL-GCB). Cell-of-origin was determined by immunohistochemistry and gene-expression profiling (GEP) using (extended)-Nano-String/Lymph2Cx analysis. Mutational profileswere identifiedwith targeted next-generation deep sequencing, including 52 B-cell lymphoma-relevant genes. O-DLBCLs, including 34 PB-DLBCLs, were predominantly classified...
Ruben Al de Groen, Ronald van Eijk, Stefan Boehringer, Tom van Wezel, Richard Raghoo, Dina Ruano, Patty M Jansen, Inge Briaire-de Bruijn, Fleur A de Groot, Karin Kleiverda, Liane Te Boome, Valeska Terpstra, Henriette Levenga, Alina Nicolae-Cristea, Eduardus Franciscus Posthuma, Isabelle Focke-Snieders, Lizan Hardi, Wietske C E den Hartog, Lara H Bohmer, Pancras C W HogendoornAnke van den Berg, Arjan Diepstra, Marcel Nijland, Pieternella J Lugtenburg, Marie José Kersten, Steven T Pals, Hendrik Veelken, Judith V M G Bovee, Arjen Cleven, Joost S P Vermaat